



Problem Statement



Every three minutes, someone in the United States is diagnosed with a blood cancer. Current chemotherapies lack precision, destroying both healthy and cancerous cells, which leads to severe side effects for patients. While newer therapies offer targeted approaches, they typically focus on a single biomarker, limiting their precision and effectiveness. Therefore, there is a critical need for therapies that can simultaneously target multiple biomarkers to **improve specificity** and aid in **highly precise targeting of cancer cells**.

Our Solution

Nanoparticle Based Drug Delivery System for Blood Cancers



Our novel product merges three technologies:

Nanoparticles that are embedded with multiple unique receptors or ligands

Chimeric antigen receptors for transmembrane targeting


Encapsulated cell-free expression systems activate pro-drug inside nanoparticle after binding

Value Proposition & Competitive Landscape

Comparison to Other Treatments

Feature	Chemotherapy	CAR-T Therapy	KuriBio's Technology
Targeting	Non-specific	Single biomarker	Multi-biomarker
Side Effects	High	Moderate	Low
Cost	Low (~\$200K)	Very High (~\$300K)	Potentially lower than CAR-T
Scalability	Easy	Hard (personalized)	High (mass-producible)



Competitive Landscape



Market Size & Growth


Global Nanomedicine Market

Expected to Account for \$950 Million USD by 2030




Business Plan & Unit Economics

Costs Per Year By Category



Unit Costs for Full Treatment





FTE = Full Time Employees
CRO = Clinical Research Organization


mAB = Monoclonal Antibody
API = Active Pharmaceutical Ingredient

CMO = Contract Manufacturer

De-Risking Through Partnerships



Currently Lab Bench, Seed Stage



Barriers to Entry

- 1 Regulatory Hurdles (FDA/EMA Approval Needed)
- 2 Limited Clinical Data for Liposomal-based NP Delivery Systems
- 3 Manufacturing Challenges to Develop Multi-targeting Characteristics
- 4 High R&D Costs - Clinical Trials & Drug Development

Acknowledgements

Cofounder Judee Sharon, Ph.D. (CEO)
Cofounder Neal Shah (CSO)
Professor Matthew Rappaport
Mentor Viktor Ström
Patent US-20240320462-A1